Is BMEA Worth Buying in 2026?

Biomea Fusion, Inc. Common Stock

STOCK PHARMACEUTICAL PREPARATIONS Updated 2026-04-19

Here’s whether Biomea Fusion, Inc. Common Stock (BMEA) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.

🟢
Bullish

Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+10.20% over 10 days); strong 1-year return of +39.0%; 3-month momentum positive (+56.7%); rising volume confirms the move (1.35x 30d avg). Concerns: RSI 82 — overbought, elevated pullback risk. Currently 28.2% off its 52-week high. Score: +6/7.

Ready to act on this? 📈 Trade on Webull

BMEA is in a confirmed uptrend, trading above both its 50-day ($1.43) and 200-day ($1.54) moving averages. With an RSI of 82.0, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +39.0% compares to +35.1% for SPY (beat the market by 3.9%). The current 28.3% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.

$10,000 invested 1 year ago → $13,899 today
vs. S&P 500 (SPY) — same period beat market by 3.9%

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

Above 200-day MA ($1.54)
Above 50-day MA ($1.43)
!RSI(14) neutral zone (30–70) — currently 82.0
Positive return (+39.0%)
!Within 10% of period high (−28.3%)
Period Range $2.21
$0.87 $3.08
RSI (14) 82.0
0 · OversoldOverbought · 100

Key Metrics

Price$2.21
Period Return+39.0%
Period High$3.08
Period Low$0.87
Drawdown−28.3%
MA-50$1.43
MA-200$1.54
RSI (14)82.0
Avg Volume (30d)1.7M
vs. SPYbeat by 3.9%
Return Rank#439 of 996

Trade BMEA

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers